Boston, MA, October 16, 2001 -- Perceptive Informatics, Inc., a subsidiary of PAREXEL International (Nasdaq: PRXL), announced today the appointment of Jay B. Zimmerman as Vice President of Operations, Medical Diagnostics. In this newly created position, Mr. Zimmerman will assume responsibility for the operations of Perceptive's medical imaging business. Perceptive's advanced medical diagnostics services are used to assess rapidly and objectively the safety and efficacy of new drugs, biologics, and medical devices in clinical trials.

Mr. Zimmerman brings to Perceptive Informatics 15 years of experience in a variety of senior management and imaging research-related roles. Most recently, Mr. Zimmerman was Co-Founder, President and Chief Operating Officer of EndPoint Imaging Solutions, Inc. (EIS), a company designed to use image-based surrogate endpoints in the drug and device approval process. Prior to EIS, he was Vice President of Clinical Operations at Photogen, Inc., a biotechnology company focused on creating therapeutic and diagnostic oncology products. Mr. Zimmerman also served as Senior Vice President and Chief Operating Officer for Clinical Trials at WorldCare, Inc. and, prior to that, as Administrative Director in the Center for Imaging and Pharmaceutical Research at Massachusetts General Hospital. Mr. Zimmerman received his Masters of Education in Administrative Policy studies, Hospital Administration from the University of Pittsburgh and a Bachelor of Science degree in Biology/Education from the University of South Carolina.

"Jay is well qualified to lead our imaging program and represents an exciting addition to our senior management team," said Mark A. Goldberg, M.D., President of Perceptive Informatics, Inc. "Perceptive's Medical Diagnostics service offerings are enhanced by his extensive imaging background which includes magnetic resonance (MR) imaging, computed tomography (CT), and ultrasound, as well as his operational experience in managing imaging programs for the bio-pharmaceutical industry."

Perceptive Informatics, Inc. develops and offers a portfolio of sophisticated and innovative technology-based products and services that facilitate clinical drug development and decrease time to peak sales. In addition to medical diagnostics services, the technology portfolio includes web-based portal solutions, Interactive Voice Response Systems (IVRS), electronic data capture, and electronic diary solutions. The Company is headquartered near Boston, MA with approximately 150 employees in offices located throughout North America and Europe. Perceptive Informatics is a subsidiary of PAREXEL International Corporation ("PRXL"), one of the largest contract pharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries.

This release may contain "forward-looking" statements regarding future results and events, including statements regarding expected financial results, future growth and customer demand that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends", "appears" and similar expressions are intended to identify forward-looking statements. PAREXEL's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the cancellation, revision, or delay of contracts, including those contracts in backlog; PAREXEL's dependence on certain industries and clients; PAREXEL's ability to win new business, manage growth, and attract and retain employees; PAREXEL's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of certain industries and clients; competition and consolidation within the pharmaceutical industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations. Such factors and others are discussed more fully in the section entitled "Risk Factors" of PAREXEL's Form 10-K for the period ended June 30, 2001, as filed with the Securities and Exchange Commission.